Pfizer's Oral Abroctinib Bests Injectable Dupixent In Atopic Dermatitis Trial

 
• By Jessica Merrill
  
Comparison scale
Pfizer says abrocitinib performed better than Dupixent in a Phase III trial • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immunological

More from Therapeutic Category